Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 181Gastrointestinal 26CNS 21Tumor-Agnostic 14Head & Neck 13Genitourinary 13Gynecologic 10Thoracic 7Other solid neoplasm 7Sarcoma 4Other hematologic neoplasm 1Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Prolactinoma 1Pituitary Neoplasms 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lapatinib × Endocrine × Clear all
NCT00939523 2020-01-22

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Cedars-Sinai Medical Center

Phase 2 Completed
9 enrolled 11 charts
Endocrine

Pituitary Neoplasms, Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡